Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 5/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341481 | 0.82 | NPC1 (0.48) | — | |
| SCHEMBL9209594 | 0.75 | FOLH1 (0.62) | MEP1BFOLH1MRGPRX4 | |
| SCHEMBL28381607 | 0.75 | MRGPRX4 (0.46) | MEP1BFOLH1MRGPRX4NR1H4 | |
| SCHEMBL27516888 | 0.73 | MEP1B (0.51) | MEP1BFOLH1NR1H4 | |
| SCHEMBL23903309 | 0.72 | LMNA (0.52) | CNR1 | |
| SCHEMBL10789439 | 0.72 | CNR1 (0.71) | CNR1 | |
| SCHEMBL27790062 | 0.72 | EPHX2 (0.65) | — | |
| SCHEMBL8531436 | 0.72 | TDP1 (0.44) | CNR1 | |
| SCHEMBL10698881 | 0.71 | FOLH1 (0.57) | MEP1BFOLH1 | |
| SCHEMBL27654141 | 0.70 | SMN1; SMN2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | CNR1 168/4885MEP1B 128/4885FOLH1 638/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CNR1 291/4885MEP1B 511/4885FOLH1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.